Clinical Trial Update: A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of acalabrutinib in Japanese adults with advanced B-cell malignancies, including relapsed/refractory CLL and mantle cell lymphoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)

Snippet

Sponsor: AstraZeneca | Conditions: Part1: Advanced B-cell Malignancies, Part2: r/rCLL and r/rMCL | Phase 1 | Status: ACTIVE_NOT_RECRUITING